Key facts
- This page summarizes John L. Higgins's Form 4 filing for LIGAND PHARMACEUTICALS INC (LGND).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 27 Dec 2022, 17:37.
John L. Higgins - 22 Dec 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)
- Reporting relationship
- Director
- Issuer ticker
- LGND
- Reported as of
- 22 Dec 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Dec 2022, 17:37:28 UTC
- Prior SEC filing
- 20 Dec 2022
- Next SEC filing
- 30 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Reardon, Attorney-in-Fact for John L. Higgins
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John L. Higgins filed Form 4 for LIGAND PHARMACEUTICALS INC (LGND) on 27 Dec 2022.
Change
- Previous filing in this sequence was filed on 20 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LGND
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +92,932
- Change %
- Price
- $0.000000
- Shares after
- 92,932
- Date
- 22 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 92,932
- Exercise price
- $67.03
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Grant to reporting person of stock options that were vested and exercisable upon grant.